-
Sector Analysis
New![]()
Dravet Syndrome (DS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Dravet Syndrome (DS) Marketed and Pipeline Drugs Report Overview Dravet syndrome is also known as severe myoclonic epilepsy of infancy (SMEI). It is a rare and severe form of epilepsy that typically begins in the first year of life. The exact cause of Dravet syndrome is usually genetic. However, seizures in affected individuals can be triggered by various factors including fever, infections, and sometimes vaccinations. These triggers can lead to prolonged and potentially life-threatening seizures known as status epilepticus. Genetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Budesonide in Eosinophilic Esophagitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Budesonide in Eosinophilic Esophagitis Drug Details: Budesonide (SHP-621) is under development for the treatment of...
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Tusamitamab ravtansine
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
![]()
Takeda Pharma – Narita Plasma Manufacturing Facility – Osaka
Equip yourself with the essential tools needed to make informed and profitable decisions with our Takeda Pharma - Narita Plasma Manufacturing Facility - Osaka report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Sector Analysis
New![]()
Crohn’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Crohn’s Disease Market Report Overview The Crohn’s disease (CD) market size across the 8MM was $9.5 billion in 2022 and is expected to achieve a CAGR of more than 4% during 2022-2032. The approval and launches of 15 pipeline, generic, and biosimilar therapies will drive the growth of the Crohn’s disease market. In 2022, the US made up the majority of total global sales. The 8MM includes the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Canada....
-
Product Insights
![]()
Lennox-Gastaut Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Lennox-Gastaut Syndrome Clinical Trials Market Overview The Lennox-Gastaut Syndrome clinical trial market research report provides an overview of the Lennox-Gastaut Syndrome Clinical trials scenario. This report provides top-line data relating to the clinical trials on Lennox-Gastaut Syndrome. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The...
-
Product Insights
![]()
Gaucher Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Gaucher Disease Clinical Trials Report Overview The Gaucher disease clinical trial report consists of 136 trials. The report provides an overview of the Gaucher disease clinical trials scenario. The report provides top-line data relating to the clinical trials on Gaucher disease. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status,...
-
Product Insights
![]()
Takeda Italia – Rieti Plasma Fractionation Plant Expansion – Latium
Equip yourself with the essential tools needed to make informed and profitable decisions with our Takeda Italia - Rieti Plasma Fractionation Plant Expansion - Latium report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
![]()
Takeda Pharma – Seestadt Aspern Research And Development Center – Vienna
Equip yourself with the essential tools needed to make informed and profitable decisions with our Takeda Pharma - Seestadt Aspern Research And Development Center - Vienna report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Subasumstat in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Subasumstat in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: TAK-981 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Subasumstat in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Subasumstat in Non-Small Cell Lung Cancer Drug Details: TAK-981 is under development for the treatment...
-
Product Insights
![]()
Takeda Pharma – Pierre-à -Bot Pharmaceutical Production Facility – Neuchatel
Equip yourself with the essential tools needed to make informed and profitable decisions with our Takeda Pharma - Pierre-Ã -Bot Pharmaceutical Production Facility - Neuchatel report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Net Present Value Model: Agenus Inc’s Balstilimab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Jazz Pharmaceuticals Plc’s Suvecaltamide Hydrochloride
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Pfizer Inc’s Etrasimod
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Pfizer Inc’s GBT-021601
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Harpoon Therapeutics Inc’s HPN-328
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Nurix Therapeutics Inc’s NX-1607
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: CStone Pharmaceuticals Co Ltd’s Fisogatinib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
![]()
Takeda Pharma – Singen Dengue Vaccine Production Facility Expansion – Baden-Wuerttemberg
Equip yourself with the essential tools needed to make informed and profitable decisions with our Takeda Pharma - Singen Dengue Vaccine Production Facility Expansion - Baden-Wuerttemberg report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.